You need to enable JavaScript to run this app.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated
Cookie Policy
Yes, I accept cookies
Steering Committee
About Us
Newsletter
Contact
Visit:
Steering Committee
About Us
Newsletter
Contact
Types
Therapeutics
Congresses
Trials
Expert Opinions
ASH 2020
AML Types
Signaling pathway mutations
Epigenetic modifier mutations
Origin
Chromosomal aberrations
Nucleophosmin mutations
Tumor suppressor mutations
Spliceosome mutations
Transcription factor mutations
Cohesin mutations
View all Types
Naval Daver
Executive Steering Committee Member
Naval Daver
Executive Steering Committee Member
Types
De novo
FLT3-ITD
IDH1
IDH2
Myelodysplasia-related
Secondary
Therapy-related
TP53
Interventions
AMG 330
Azacitidine
Bispecific antibodies
Blinatumomab
CAR T-cell therapy
CD123 CAR-T
CD33 CAR-T
Checkpoint inhibitors
CPX-351
Cytarabine
Durvalumab
Flotetuzumab
Gemtuzumab ozogamicin
Gilteritinib
Hypomethylating agents
Idarubicin
Ipilimumab
Ivosidenib
Magrolimab
Nivolumab
Pembrolizumab
Venetoclax
Events
ASCO 2020
ASH 2018
ASH 2019
EHA 2017
EHA 2018
EHA 2020
ESH 2020
NCRI AML Academy 2020
SOHO 2020
Trials
5F9005
ADMIRAL
NCT03248479
All
|
4 Articles
|
9 Videos
|
2 Podcasts